Sol-gel technologies announces management realignment

Ness ziona, israel, july 15, 2024 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a phase 3 clinical trial of sgt-610 (patidegib gel, 2%) for gorlin syndrome, and with two approved large-category dermatology products, twyneo® and epsolay®, today announced that the chief executive officer, dr. alon seri-levy, has recently advised the sol-gel board of directors of his desire to step down from his position as ceo and member of the board.
SLGL Ratings Summary
SLGL Quant Ranking